Zitat des Tages von Vivek Ramaswamy:
For some companies, going public makes the most sense. For others, remaining private is preferable.
The more general skepticism about another millennial that likes to claim they're disrupting another industry - that doesn't serve me well.
I really was inspired by the possibility of more directly being involved in the development of drugs myself.
I'd encourage more young people to apply their talents beyond finance and consulting and to think about reshaping how medicines are brought to market and how the business is run.
There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.
Our philosophy is to attract top talent and incentivise them to succeed. We have some of the top talent in the entire industry.
Our goal is to continue to build the pipeline to fight all aspects of disease for all forms of dementia.
Roivant does not view - and has never viewed - Axovant as simply a 'vehicle' for developing intepirdine, but instead as a platform for the development of high-impact drugs in dementia and the neuroscience field more generally.
The most important ingredient for the success of any company is the quality of its people, starting with its leadership team.
I believe the pharma company of the future isn't going to be old-school.
